Best Stocks To Own For 2015

For the month of July, U.S. home sales reached an annualized rate of 5.5 million, up 4% from June and 11% higher than the rate in July 2012. But as with most things related to real estate, it is all about location, location and location.

All-cash transactions accounted for 40% of U.S. house sales in July, up from 35% in June and 31% higher than all-cash sales in July of 2012. Month-over-month increases in all-cash purchases in the country’s largest metropolitan areas include Dallas (82%), St. Louis (66%), Los Angeles (32%), Seattle (21%) and Phoenix (21%).

The data comes from RealtyTrac’s latest Residential & Foreclosure Sales Report released Thursday morning. A company executive puts the numbers in perspective:

Low inventory of homes available for sale is proving to be a double-edged sword in many local housing markets that have bounced back quickly from the real estate slump. Home prices are accelerating rapidly in these markets thanks to the combination of low supply and strong demand. However, counter to the national trend, sales volume in these markets is down even as the percentage of cash sales rises, indicating there is still strong demand but that buyers who need financing to purchase are increasingly left out in the cold.

Best Stocks To Own For 2015: Atrion Corp (ATRI)

Atrion Corporation (Atrion), and its subsidiaries, develop and manufacture products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. During the year ended December 31, 2011, the Company’s fluid delivery products accounted for 38% of the Company’s revenues. These products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes, and produce specialized intravenous sets for use in numerous applications, including anesthesia and oncology.

The Company’s cardiovascular products accounted for 29% of its revenues during 2011. The Company’s principal cardiovascular product is the Myocardial Protection System (MPS2), a technology that delivers essential fluids and medications to the heart during open-heart surgery. The MPS2 integrates key functions relating to the delivery of solutions to the heart, such as varying the rate and ratio of oxygenated blood, crystalloid, potassium and other additives, and controlling temperature, pressure and other variables to allow simpler, more flexible management of this process, indicating improved patient outcomes. The MPS2 is the device used in open-heart surgery that allows for the mixing of drugs into the bloodstream without diluting the blood. The MPS2 employs advanced pump, temperature control and microprocessor technologies and includes a line of disposable products. It also develops and manufactures other cardiovascular products that include cardiac surgery vacuum relief valves; Retract-O-Tape silicone vessel loops for retracting and occluding vessels in minimally inva! sive surgical procedures; inflation devices for balloon catheter dilation, stent deployment and fluid dispensing, and Clean-Cut rotating aortic punch and PerfectCut Aortotomy System, both of which are used in heart bypass surgery to make a precision opening in the heart for attachment of the bypass vessels.

The Company’s ophthalmic products accounted for 17% of its revenues during 2011. The Company is a manufacturer of contact lens disinfection cases. It also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. The Company’s other medical and non-medical products accounted for 16% of its revenues during 2011. These product lines consist of instrumentation and associated disposables used to measure the activated clotting time of blood. In addition, it manufactures and sells a line of products designed for safe needle and scalpel blade containment. It is also the manufacturer of inflation syst ems and valves used in marine and aviation safety products. The Company manufactures inflation systems and valves for products, such as life vests, life rafts, inflatable boats, survival equipment and other inflatable structures. The Company also produces one-way and two-way pressure relief valves for use on electronics cases, munitions cases, pressure vessels, transportation container cases, escape slides, and many other medical and non-medical applications.

The Company market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It sells its products through a sales force which consists of direct sales personnel, independent sales representatives and distributors. It offers customer service, training and education, and technical support such as field service, spare parts, maintenance and repair for certain of its products. The Company’s medical products and other components are produced at facilities in ! Florida, ! Alabama and Texas.

Advisors’ Opinion:

  • [By Seth Jayson]

    There’s no foolproof way to know the future for ATRION (Nasdaq: ATRI  ) or any other company. However, certain clues may help you see potential stumbles before they happen — and before your stock craters as a result.

Best Stocks To Own For 2015: Clicksoftware Technologies Ltd (CKSW)

ClickSoftware Technologies Ltd. (ClickSoftware), incorporated in 1979, is a provider of software products and solutions for workforce management and optimization for the service sector. The Company derives revenues from the licensing of its software products and the provision of consulting and support services. It also generates revenues from Cloud-based solutions. under software as a service (SaaS) model. ClickSoftware’s solutions are grouped into four main suites which together comprise its Service Optimization Suite: Field Service Daily Suite, Mobility Suite, Roster (Shift Planning) Suite and Forecasting and Planning Suite. Additionally, it offers variations of its products for certain vertical markets, including Mid-Market Package – Installation, Maintenance and Repair Services (ClickIMRS) and Service Tycoon. Its products include: ClickSchedule, ClickAnalyze, ClickLocate, ClickContact, ClickRoster, ClickPlan, and ClickForecast. In March 2014, the Company acquired Xor a Inc., a cloud-based mobile workforce management.

Field Service Daily Suite covers automatic decision making and optimization support to manage field service operations: commencing from appointment booking and scheduling during the period around the day of service, followed by real time scheduling and optimization during the day of service and culminating with reports and business metrics analytics after the day of service. Roster (Shift Planning) Suite covers shift planning needs for both the manager, as well as the employee to optimize the balance between staffing levels needed for serving customers and managing labor costs, and employee preferences. This suite is offered in several configurations for different industry verticals ranging from police forces to contact centers, and more. Mobility Suite covers the needs of the mobile individual and back-office staff for field data communication, such as sending jobs from the back office to the person’s hand-he ld device, and the person’s ability to accept/decline the ! job, report on progress and job completion, as well as capturing customers’ signatures, or sending the person’s own time sheet to the back office. Geography support, such as travel guidance and information about underground equipment are also covered.

ClickSchedule optimizes service scheduling and routing to improve workforce productivity by balancing customer, service and asset resources, and organizational preferences, including contractual commitments, priority, drive time, skills, and service and asset resources availability. ClickAnalyze provides reporting, monitoring and service business analytics for workforce performance measurement and strategic decision support. It enables analysis of key performance indicators, including resource productivity, operational costs, and responsiveness to customers.

ClickLocate (LBS) captures the location information of a field service engineer and/or his or her vehicle obtained via GPS or other te chnology and integrates it with ClickSchedule for use in optimized scheduling. LBS then enables service organizations to improve their service operations by allowing them to make decisions and take actions based on location information, including near real-time engineer locations. ClickContact is a customer interaction management solution that enables self-service appointment booking, order updating, automatic customer notifications and customer satisfaction surveying. From scheduling the initial appointment through enabling a post-service follow-up survey, ClickContact provides customer interaction management throughout the service lifecycle.

ClickRoster provides interactive and automated workforce shift planning based on forecasted workload by quantities and skill requirements, rules and regulations, working contracts, engineer skills, calendar and preferences. ClickPlan provides interactive and automated workforce planning for staffing and deployment of the f ield workforce based on forecasted workload. It is designed ! to enable! service organizations to resolve workforce shortages and surpluses weeks and months in advance. ClickForecast provides field service workload forecasting to enable companies to project workforce capacity. It enables service managers, marketing, and sales to determine the demand levels of customers, and to create multiple forecast scenarios, each with different business assumptions. (ClickIMRS) is a pre-configured package that has been tailored to the needs of small and mid-sized companies. ClickIMRS features pre-configured scheduling and reporting that reduces the expense, time and effort required to custom-design and program schedules and reports. In addition, the ready-to-use reports provide insight into service operations and streamline decision-making on the part of both service management and dispatchers.

ClickSoftware Cloud Services include two Web-based offerings of its complete Service Optimization Suite. ClickCloud offers medium and market ent erprise customers an alternative to on-premises deployment of the Service Optimization Suite. ClickCloud also enables a hybrid information technology (IT) model, which is a solution comprised of a mix of Cloud and on-premises deployment ClickExpress offers the customers to be up and running within a relatively short period of time, with its products.

Advisors’ Opinion:

  • [By Sean Williams]

    Optimize your buying
    Software companies these days are being judged not just by how many new contracts they gained during the current quarter, but by how well they’re prepared to deal with the transition to cloud platforms. Supply-chain and workforce-optimization software developer ClickSoftware Technologies (NASDAQ: CKSW  ) looks well poised to take advantage of these trends and has no business, in my opinion, being anywhere near a 52-week low.

  • [By Evan Niu, CFA]

    What: Shares of ClickSoftware (NASDAQ: CKSW  ) have plunged today by as much as 13% after the company warned that second-quarter results would fall short of expectations.

Best Stocks To Own For 2015: BreitBurn Energy Partners L.P.(BBEP)

BreitBurn Energy Partners L.P. engages in the acquisition, exploitation, and development of oil and gas properties in the United States. The company?s properties include natural gas, oil, and midstream assets comprising fields in the Antrim Shale in Michigan, and the New Albany Shale in Indiana and Kentucky; and fields in the Evanston and Green River basins in southwestern Wyoming, the Wind river and Big Horn basins in central Wyoming, the Powder River basin in eastern Wyoming, the Los Angeles basin in California, and fields in Florida?s Sunniland Trend. As of December 31, 2011, its total estimated proved reserves were 151.1 million barrels of oil equivalent. BreitBurn GP, LLC serves as the general partner to the company. BreitBurn Energy Partners L.P. was founded in 2006 and is headquartered in Los Angeles, California.

Advisors’ Opinion:

  • [By Tyler Crowe]

    If you’re looking for income investments, then it’s awfully hard to argue with the massive distribution payments from LINN Energy (NASDAQ: LINE  ) (NASDAQ: LNCO  ) , Breitburn Energy Partners (NASDAQ: BBEP  ) , and Vanguard Natural Resources (NASDAQ: VNR  ) . Thing is, though, income investments need both a decent yield and a level of certainty that it will keep that distribution going for many years to come. Other than being high-yielding investments, they are also all master limited partnerships, which means you need to look beyond just the operations to see how these companies will stand the test of time.

  • [By Daniel Gibbs]

    One investment vehicle that any investor interested in income should be familiar with is the master limited partnership, or MLP, as they are some of the best income investments available today. Most master limited partnerships are in the business of owning and operating oil and gas pipelines such as Kinder Morgan Energy Partners (NYSE: KMP  ) or Enbridge Energy Partners (NYSE: EEP  ) . However, there are some MLPs that actually operate oil and gas wells such as Breitburn Energy Partners (NASDAQ: BBEP  ) and Mid-Con Energy Partners (NASDAQ: MCEP  ) . In this article, we will discuss how these investments work and why they deserve a place in your income portfolio.

  • [By Robert Rapier]

    VNR is one of 14 companies/partnerships that are categorized as exploration and production, or “upstream.” Other notable entries in this category include BreitBurn Energy Partners (Nasdaq: BBEP), Linn Energy (Nasdaq: LINE), Memorial Production Partners (Nasdaq: MEMP), QR Energy (NYSE: QRE), Legacy Reserves (Nasdaq: LGCY), EV Energy Partners (Nasdaq: EVEP), and Mid-Con Energy Partners (Nasdaq: MCEP).

Best Stocks To Own For 2015: Abraxas Petroleum Corp (AXAS)

Abraxas Petroleum Corporation is an independent energy company primarily engaged in the acquisition, exploitation, development and production of oil and gas in the United States and Canada. As of December 31, 2011, the Company’s estimated net proved reserves were 29.0 million barrels of oil equivalent (MMBoe), (including reserves attributable to its 34.7% equity interest in the proved reserves of Blue Eagle), of which 53% were classified as proved developed, 54% were oil and natural gas liquids (NGL’s) and 94% by PV-10 were operated. Its daily net production during the year ended December 31, 2011, was 3,484 barrels of oil equivalent per day, of which 45% was oil or liquids. Its oil and gas assets are located in four operating regions in the United States, the Rocky Mountain, Mid-Continent, Permian Basin and onshore Gulf Coast, and in the province of Alberta, Canada.

The Company’s properties in the Rocky Mountain region are located in the Williston Basin of North Dakota and Montana and in the Green River, Powder River and Unita Basins of Wyoming and Utah. In this region, its wells produce oil and gas from various reservoirs, including the Niobrara, Turner, Bakken and Three Forks formations. Well depths range from 7,000 feet down to 14,000 feet. The Company’s properties in the Mid-Continent region are primarily located in the Arkoma Basin and principally produce gas from the Hartshorne coals at 3,000 feet. Its properties in the Permian Basin region are primarily located in two sub-basins, the Delaware Basin and the Eastern Shelf. In the Delaware Basin, its wells are located in Pecos, Reeves, and Ward Counties, Texas and produce oil and gas from multiple stacked formations from the Bell Canyon at 5,000 feet down to the Ellenburger at 16,000 feet.

In the Eastern Shelf, its wells are principally located in Coke, Scurry, Midland, Mitchell and Nolan Counties, Texas and produce oil and gas from the Strawn Reef form ation at 5,000 to 7,500 feet and oil from the shallower Clea! rfork formation at depths ranging from 2,300 to 3,300 feet. The Company’s properties in the onshore Gulf Coast region are located along the Edwards trend in DeWitt and Lavaca Counties, Texas and in the Portilla field in San Patricio County, Texas. In the Edwards trend, its wells produce gas from the Edwards formation at a depth of 14,000 feet and in the Portilla field, its wells produce oil and gas from the Frio sands and the deeper Vicksburg from depths of approximately 7,000 to 9,000 feet. In addition, the Company also owns a 34.7% equity interest in a joint venture targeting the Eagle Ford in South Texas. Its properties in the province of Alberta, Canada are located in the Pekisko fairway and the Nordegg/Tomahawk area of Central Alberta.

As of December 31, 2011, the Company leased approximately 20,835 net acres, primarily in counties located on the Nesson Anticline and in areas west, including Rough Rider and Lewis & Clark in North Dakota and in Sheridan Co unty, Montana, which are prospective for the Bakken and Three Forks formations. During the year ended December 31, 2011, the Company drilled two operated wells and participated in an additional 19 gross (1.0 net) non-operated wells. In July 2011, Abraxas purchased a used Oilwell 2000 horsepower diesel electric drilling rig. In August 2010, the Company formed a joint venture, Blue Eagle, with Rock Oil to develop its acreage in the Eagle Ford Shale play. As of December 31, 2011, the Company owned a 34.7% interest in Blue Eagle. During 2011, Blue Eagle drilled, completed or participated in three gross (2.4 net) wells and added approximately 3,800 net acres to its holdings, principally in McMullen County, Texas.

As of December 31, 2011, the Company leased a total of approximately 20,720 gross (17,800 net) acres in the southern Powder River Basin, of which 17,800 gross (15,700 net) acres were located in the Brooks Draw field of Converse and Niobrara Counties, Wyoming . In addition, it owns approximately 2,100 net acres in sout! hern Camp! bell County, Wyoming which are held by production and are near the Crossbow field operated by EOG Resources, Inc. and other recent horizontal activity. As of December 31, 2011, the Company leased 6,880 net acres in western Alberta. In 2011, it drilled or completed six gross (6 net) wells in the Twining area. In the emerging southern Alberta Basin Bakken play of Toole and Glacier Counties, Montana, the Company leased approximately 10,000 gross/net acres under long-term leases or direct mineral ownership. As of December 31, 2011, it leased approximately 5,600 gross/net acres in Nolan County, Texas. In 2011, the Company drilled three wells in the Spires Ranch offsetting the prolific Nena Lucia field.

Advisors’ Opinion:

  • [By Value Investor]

    Abraxas Petroleum Corporation (AXAS) is a small cap exploration and production company based in San Antonio, Texas. The company has a market cap of $472 million and has been trending higher since last year in terms of stock price. The company is currently trading at a price of $5 and this article discusses why the upside will continue.

  • [By Lisa Levin] Related IIN Morning Market Movers Morning Market Losers Related AXAS Abraxas Petroleum Corp. (AXAS) in Focus: Stock Moves 6.4% Higher – Tale of the Tape Will Noble Energy Disappoint This Quarter? – Analyst Blog

    Intricon (NASDAQ: IIN) shares gained 33.98% to touch a new 52-week high of $6.23 after the company reported Q1 results.

  • [By Monica Gerson] Related AMKR Stocks to Watch for September 12, 2013 Seven Dividend-Paying Tech Stocks Analysts Are Bullish On Related AXAS EXCO Resources to Offer Senior Notes – Analyst Blog Abraxas (AXAS) Shares March Higher, Can It Continue? – Tale of the Tape

    Amkor Technology (NASDAQ: AMKR) shares gained 1.63% to touch a new 52-week high of $7.46. Amkor Technology’s PEG ratio is 0.94.

  • [By Monica Gerson]

    Abraxas Petroleum (NASDAQ: AXAS) is estimated to post its Q4 earnings at $0.04 per share on revenue of $23.05 million.

    Broadwind Energy (NASDAQ: BWEN) is projected to post a Q4 loss at $0.19 per share on revenue of $56.54 million.

Best Stocks To Own For 2015: Holcim Ltd (HOLN)

Holcim Ltd (Holcim) is a Switzerland-based holding company that specializes in the manufacture, distribution and marketing of building materials. The Company operates four business segments, including Cement, Aggregates, Other construction materials and services, and Corporate. The Cement segment is engaged in the development of cement and comprises clinker and other cementitious materials, among others. The Aggregates business segment includes crushed stone, gravel and sand. The Other construction materials and services business segment comprises ready-mix concrete, concrete products, asphalt, construction and paving, and trading, among others. Additionally, other construction materials and services segment provides environmental services, including waste management, among others. The Corporate segment is engaged in holding activities and general management. It operates through subsidiaries in Asia Pacific, Latin America, Europe, North America, Africa and Middle East regions . Advisors’ Opinion:

  • [By Sofia Horta e Costa]

    Holcim Ltd. (HOLN) lost 0.9 percent to 68.15 francs in Zurich. Bank of America Corp.’s Merrill Lynch unit cut its rating on the world’s largest cement maker to underperform, similar to a sell recommendation, from neutral. Merrill Lynch cited the company’s exposure to emerging markets.

Best Stocks To Own For 2015: Blackbaud Inc.(BLKB)

Blackbaud, Inc. provides software and related services for nonprofit organizations. The company offers The Raiser?s Edge, a software application to manage constituent relationship management (CRM) and fundraising activity; Blackbaud CRM, a Web-based CRM solution that addresses the needs of mid-size, large, and federated chapter based nonprofit organizations; eTapestry, a software-as-a-service (SaaS) donor management and fundraising solution for smaller nonprofits; Blackbaud NetCommunity, an Internet marketing and communications tool to build interactive Websites and manage email marketing campaigns; Sphere eMarketing, a SaaS that provides applications to manage e-marketing, communications, programs, services, and online fundraising; Everyday Hero, an event-based online fundraising solution; and BlackbaudNow for developing an online presence and accepting online donations. It also provides The Financial Edge, an accounting application; The Education Edge, a student informa tion management system; Blackbaud?s Student Information System, which links student information across various campus offices, as well as organizes the admissions and registrar?s processes; and Blackbaud for Small Schools, a SaaS solution that helps schools with their registration process, as well as gives parents, students, and faculty an online access to school information. In addition, the company offers The Patron Edge, a ticketing management solution; Blackbaud Direct Marketing that helps in managing direct marketing campaigns with various media and channels; Sphere Friends Asking Friends software product to launch and manage online event fundraising Websites; and Altru, a SaaS solution that helps general admissions arts and cultural organizations in their operation. Further, it provides consulting and education, analytics, maintenance, and payment processing services. Blackbaud, Inc. was founded in 1981 and is headquartered in Charleston, South Carolina.

Advisors’ Opinion:

  • [By Seth Jayson]

    Blackbaud (Nasdaq: BLKB  ) is expected to report Q1 earnings on May 1. Here’s what Wall Street wants to see:

    The 10-second takeaway
    Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Blackbaud’s revenues will expand 20.7% and EPS will expand 11.8%.

Best Stocks To Own For 2015: Plum Creek Timber Company Inc.(PCL)

Plum Creek Timber Company, Inc. is a publicly owned real estate investment trust (REIT). The trust owns and manages timberlands in the United States. Its products include lumber products, plywood, medium density fiberboard, and related by-products, such as wood chips. The trust also focuses on mineral extraction and natural gas production, communication, and transportation. Plum Creek Timber Company was founded in 1989 and is based in Seattle, Washington.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Among stocks in the S&P 500, CBRE Group (CBG) has dropped 5.5% to $23.05 after it reported a profit of 30 cents a share, missing forecasts for 33 cents. Aflac (AFL), meanwhile, has fallen 3% to $65 after it reported a profit of $1.47, missing estimates for $1.48 on weakness in Japan. Plum Creek Timber (PCL) has dropped 1.3% to $45.76 after announcing that it would sell 12.1 million shares of stock at $45.

  • [By Ben Levisohn]

    Shares of Rayonier have plunged 15% to $46.97 at 12.36 p.m., but its fall doesn’t seem to have damaged other timber companies. Weyerhaeuser (WY) has gained 3.7% to $31.43 after it reported a profit of 27 cents today, beating estimates of 21 cents. Plum Creek Timber (PCL) is little changed at $49.47 and Boise Cascade (BCC) has risen 1.1% to $27.83.

Best Stocks To Own For 2015: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t h e treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors’ Opinion:

  • [By MONEYMORNING.COM]

    If the Apple stock split does succeed in putting splits back into vogue, these companies are most in need of one:

    Priceline Group Inc. (Nasdaq: PCLN) – Share price: $1,232.43
    The online travel company famous for its commercials with William Shatner actually did a 1-for-6 reverse stock split back in 2003 following the dot-com bust. That bad memory has probably been a factor holding PCLN back from doing a stock split. But at this point a 10-to-1 split would make perfect sense. Chipotle Mexican Grill Inc. (NYSE: CMG) – Share price: $568.09
    The Mexican restaurant chain has enjoyed a lot of growth and is a star player in the casual dining sector. It has never had a stock split. Management has frequently scoffed at the idea of a stock split, but that doesn’t mean it won’t happen. Until about a year ago, Apple said the same thing. Autozone Inc. (NYSE: AZO) – Share price: $533.84
    AutoZone is a retailer and a U.S. distributor of automotive replacement parts and accessories. The company has had two 2-for-1 splits in its history, in 1992 and 1994, so it certainly is due. Netflix Inc. (Nasdaq: NFLX) – Share price: $421.54
    Growing from a by-mail DVD rental and subscription service into a full-blown Internet-based TV network has pushed NFLX to impressive heights. Netflix had one 2-for-1 split back in 2004. But the dramatic fall of the stock back in 2011 – from just over $300 to $50 – no doubt has kept the company from pulling the trigger on a stock split. The price will have to go even higher to convince management it’s safe to split. Intuitive Surgical Inc. (Nasdaq: ISRG) – Share price: $373.90
    Intuitive Surgical designs, manufactures, and markets its own da Vinci Surgical Systems and related instruments and accessories. As ISRG has pulled back from highs of about $575 a share over the past couple of years, a stock split for Intuitive would seem counterintuitive for now. Amazon.com Inc. (Nasdaq

  • [By Ben Levisohn]

    This year, Celgene has dropped 9.9%, even as other giant biotech companies like Biogen Idec (BIIB), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) has gained 7% or more. Even the SPDR S&P Biotech ETF (XBI) has managed to stay above water despite big March losses.

  • [By Ben Levisohn]

    Stocks rose today as jobless despite a weak GDP reading as jobless claims fell and merger mania gripped the food stocks. Shares of Tyson Foods (TSN), Hillshire Brands (HSH), Merck (MRK), Biogen Idec (BIIB), and SunEdison (SUNE) helped lead the market higher.

Best Stocks To Own For 2015: BioTime Inc (BTX)

BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan’s assets, including Glycosan’s Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company’s stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.

HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molec ules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascu lar and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.

The Company’s blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pr essure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.

Human Embryonic Stem Cell Lines for Research Use

Combined with the Company’s ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI’s six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.

The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.

Human Embryonic Progenitor Cells

Through the Company’s subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerat e technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.

Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agree ment with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company’s California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.

hES Cells Carrying Genetic Diseases

The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).

ESpan Cell G rowth Media

The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.

ESpy Cell Lines

The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.

HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices

HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactu red using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.

Advisors’ Opinion:

  • [By Brian Pacampara]

    Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, biotechnology company BioTime (NYSEMKT: BTX  ) has received the dreaded one-star ranking.

  • [By John Udovich]

    Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector: